Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab
Authors:
- 26 June 2008
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 246 (10) , 1379-1381
Abstract
Background To study the effect on untreated fellow eyes of eyes treated with an intravitreal injection of bevacizumab. Methods Bevacizumab (1.25 mg/0.05 ml) was injected into the vitreous cavity of one eye (the first eye) as a preoperative adjunctive therapy for proliferative diabetic retinopathy; vitrectomy was performed 1 week later. Immediately after vitrectomy, bevacizumab (1.25 mg/0.05 ml) was injected into the fellow eye (the second eye) followed by vitrectomy 1 week later. Aqueous humor samples were obtained from both eyes in five cases just before intravitreal injection of bevacizumab and just before vitrectomy 1 week later. Vascular endothelial growth factor (VEGF) concentrations in the aqueous humor were measured by enzyme-linked immunosorbent assay (ELISA). Results VEGF concentrations in the aqueous humor of the first eyes ranged from 146 to 398 pg/ml (mean, 302±100 pg/ml) before intravitreal injection of bevacizumab; 1 week later, the VEGF concentrations in the injected eyes were less than 31 pg/ml, the lower limit of the ELISA, in all cases (p<0.001). The concentrations in the uninjected fellow eyes ranged from 181 to 551 pg/ml (mean, 382±119 pg/ml). Conclusions There seemed to be no or a minimal effect of the intravitreal injections of bevacizumab on the uninjected fellow eyes.Keywords
This publication has 12 references indexed in Scilit:
- Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic RetinopathyArchives of Ophthalmology (1950), 2007
- Pharmacokinetics of Intravitreal Bevacizumab (Avastin)Ophthalmology, 2007
- Intravitreal Injection of Bevacizumab (Avastin) as Adjunctive Treatment of Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 2006
- Vanishing Disc Neovascularization Following Intravitreal Bevacizumab (Avastin) InjectionArchives of Ophthalmology (1950), 2006
- Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 2006
- USE OF INTRAVITREAL BEVACIZUMAB AS A PREOPERATIVE ADJUNCT FOR TRACTIONAL RETINAL DETACHMENT REPAIR IN SEVERE PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2006
- Intracameral Bevacizumab for Iris RubeosisAmerican Journal of Ophthalmology, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGERetina, 2006
- Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patientsGraefe's Archive for Clinical and Experimental Ophthalmology, 2004
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994